🇺🇸

Distress Insolvency

· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 15, 2026

This brief covers a single filing from Lipella Pharmaceuticals Inc., which filed for Chapter 11 bankruptcy on March 30, 2026, and subsequently entered into an Asset Purchase Agreement with XRAIY to sell substantially all of its assets. The sale was approved by the Bankruptcy Court on June 4, 2026. The company explicitly warns that trading in its common stock during the Chapter 11 case is highly speculative and may bear little or no relation to actual recovery for stockholders. With no period-over-period comparisons, insider trading activity, forward-looking guidance, or capital allocation data available in the enriched filing, the actionable insights are limited to the bankruptcy proceedings and the asset sale. The key development is the court-approved sale, which effectively ends the company's operations and leaves equity holders with likely zero recovery. This is a classic end-stage bankruptcy event with no turnaround potential, making it a high-risk situation for any remaining shareholders.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 14, 2026

Both filings on July 14, 2026, involve voluntary exchange transfers—D-Wave Quantum moving from NYSE to Nasdaq and Trinity Capital moving from Nasdaq to NYSE/NYSE Texas—neither triggered by financial distress or listing non-compliance. No period-over-period financial data, insider transactions, forward guidance, or capital allocation changes were disclosed in either filing, limiting the depth of quantitative trend analysis. The delistings are purely administrative listing venue changes with no operational or financial impact, resulting in neutral sentiment (materiality 4-5/10). For a corporate distress & bankruptcy stream, these events are non-events; no bankruptcy, going concern, or delisting-for-cause signals are present. The digest therefore focuses on the absence of distress signals and the benign nature of these voluntary transfers.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 13, 2026

The three filings paint a stark picture of distress among micro-cap companies listed on Nasdaq, with all three facing delisting or imminent suspension due to non-compliance with listing standards. Pluri Inc., Actelis Networks Inc., and BNB Plus Corp. all received negative delisting or non-compliance notices within a single week (July 7-10, 2026), indicating a concentrated wave of corporate distress. None of the companies provided forward-looking guidance, insider trading activity, or capital allocation data in their filings, suggesting a lack of strategic communication or financial flexibility. The common theme is a failure to meet minimum market value or bid price requirements, with all three companies either already trading on the OTCQB Venture Market or facing imminent transfer. The absence of any positive period-over-period trends or recovery plans underscores the severity of their situations, making these high-risk, low-recovery scenarios for equity holders.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 10, 2026

All four filings in this digest are Nasdaq-listed companies receiving non-compliance or delisting notices, underscoring a concentrated wave of distress among micro-cap and small-cap issuers. GeoVax Labs, NanoVibronix, Lakeside Holding, and Mercer International each face minimum bid price or stockholders' equity violations, with NanoVibronix at the highest risk due to a prior reverse split that disqualifies it from a standard cure period. Lakeside Holding has already received a second 180-day extension, indicating persistent price weakness. No period-over-period financial data, insider activity, capital allocation, or forward-looking guidance was disclosed in these 8-K filings, limiting quantitative trend analysis. The overarching theme is a liquidity and market confidence crisis, with no clear catalysts for recovery and a high probability of at least one delisting event. Investors should monitor these names for potential bankruptcy or going-concern triggers as they exhaust compliance remedies.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 09, 2026

This intelligence stream reveals a severe cluster of corporate distress signals concentrated in micro-cap and pre-revenue biotech companies, with 5 of 8 filings involving Nasdaq/NYSE American non-compliance or delisting threats. The most critical development is the termination of the Shutterstock/Getty Images merger, a high-profile deal collapse driven by UK regulatory conditions, which signals heightened antitrust risk in digital content M&A. The remaining filings paint a bleak picture of liquidity crises: Kyverna Therapeutics is burning cash and extending loan draw deadlines with new revenue covenants, while Nauticus Robotics is issuing 10% cumulative preferred stock to raise capital, indicating desperate financing terms. The three Nasdaq deficiency notices (Onfolio, Hydrofarm, Prairie Operating) and one NYSE American compliance plan (Splash Beverage) represent a systemic wave of micro-cap distress, with all four companies trading below $1.00 and facing potential delisting. Period-over-period data from the enriched filings shows no positive revenue or margin trends—only deteriorating liquidity, increasing debt burdens, and regulatory overhang. The overarching theme is a 'distress cascade' in small-cap equities, where falling stock prices trigger listing compliance issues, which in turn restrict capital access and accelerate financial deterioration.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 08, 2026

The 31 filings reveal a bifurcated corporate landscape: while several companies (AEP Texas, Sterling Infrastructure, Energy Transfer) secure large-scale financing for growth and infrastructure, a significant cluster faces acute distress signals—Nasdaq non-compliance (Borealis Foods, Nocera, Future FinTech), high-cost emergency financing (XCF Global, Newton Golf, Clean Energy Technologies), and failed clinical/SPAC deals (Alector, Aimei Health). Period-over-period data is sparse, but insider activity shows CEO Woodman personally lending $20M to GoPro, a strong vote of confidence. Capital allocation trends include debt refinancings (Civeo, Voyager, CPKC) and bolt-on M&A (Byrna, Tarsus, ReposiTrak). The distressed cohort is concentrated in micro-cap and pre-revenue biotech/tech, while mid-cap energy and infrastructure firms demonstrate financial strength.

31 high priority 31 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 07, 2026

The July 7, 2026, filing batch reveals a bifurcated corporate landscape. On one side, several companies are executing strategic balance sheet improvements, including debt refinancings (Oceaneering, Oncology Institute, UGI Corp), credit facility expansions (Suncrete, Postal Realty Trust), and a major non-dilutive royalty deal (MeiraGTx). Conversely, a cluster of filings signals acute financial distress, characterized by high-cost emergency financing (NextNRG, CDT Equity, Polar Power), equity-based debt settlements (Interactive Strength), and going-concern-like PIPE offerings (Vivos Therapeutics). A notable sector-wide trend is the coordinated benchmark provider switch by seven 21Shares crypto ETFs, a purely operational shift with no financial impact. The most material M&A activity includes Vertex's $10B acquisition of Crinetics and Iridium's acquisition of Aireon, both strategically significant. Overall, the data points to a 'haves and have-nots' dynamic where well-capitalized firms are securing favorable terms, while cash-strapped companies are resorting to dilutive or high-cost capital, a classic late-cycle distress signal.

44 high priority 44 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 06, 2026

This digest covers 50 SEC filings from July 6, 2026, revealing a pronounced wave of corporate distress across small-cap and micro-cap companies, particularly in the biotech and technology sectors. Key themes include a cluster of Nasdaq non-compliance notices (CISO Global, Cytosorbents, Polar Power), aggressive debt restructuring under duress (BioXcel Therapeutics, P3 Health Partners), and dilutive financing rounds (FreeCast, Mitesco, iPower). Period-over-period comparisons, where available, show severe liquidity constraints, with companies like Polar Power reporting only $144,000 in stockholders' equity against a $2.5M minimum. Insider activity is mixed, with some executives providing cash infusions (Greenpro Capital) while others are issuing shares to cancel debt (IGC Pharma). The M&A landscape is bifurcated, with a large, healthy acquisition of Crinetics by Vertex ($10B) contrasting with distressed asset sales and reverse mergers (ClearOne/Cortigent, Professional Diversity Network). Overall, the data signals a high-risk environment for marginal companies, with a clear catalyst calendar of compliance deadlines and restructuring milestones through late 2026.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 02, 2026

The 50 filings reveal a pronounced bifurcation in corporate health: while several companies are securing substantial capital (BridgeBio $1B, NextDecade $3.5B, Neurogene $134.8M) and extending credit lines (Haverty +$20M, Cheniere +$500M), a cluster of distressed firms are fighting for survival through high-cost debt (American Rebel 36.6% effective rate), repeated maturity extensions (CareView 15th amendment), and reverse stock splits (Snail 1-for-5). Distress signals dominate: 5 companies received Nasdaq deficiency notices (RenovoRx, HeartBeam, ALT5 Sigma, Boxlight, Snail), 1 approved liquidation (Origin Materials), and 1 faces delisting (Boxlight). Period-over-period data is sparse but shows HUMBL's revenue growing 20% YoY while losses widen, and Centrus Energy securing a $900M DOE contract but with first capacity not until 2029. Insider activity is limited but includes CEO Nicholas Liuzza receiving shares at a premium in Beeline Holdings. The overarching theme is capital access as a differentiator—well-capitalized firms are investing for growth, while cash-strapped firms resort to dilutive or expensive financing.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 01, 2026

This digest of 50 pre-analyzed SEC filings from July 1, 2026, reveals a pronounced bifurcation in corporate health. On one side, a wave of distress signals is concentrated among small-cap and micro-cap companies, with 8 filings directly involving bankruptcy, going concern, delisting, or severe liquidity crises. These include InnSuites Hospitality Trust (IHT) receiving a delisting notice due to a stockholders' deficit, Stratus Properties (STRS) voluntarily liquidating, and multiple companies like Nuvve (NVVE) and Trio Petroleum executing reverse splits or taking on high-interest debt. Conversely, a separate cohort of larger, more established firms is proactively strengthening their balance sheets and extending maturities, exemplified by Peabody Energy (BTU) upsizing and extending its credit facility, FTI Consulting (FCN) increasing its revolver to $1.5B, and Kohl's (KSS) extending its facility by five years. A third theme is the aggressive use of dilutive financing, particularly through convertible notes and equity lines, by companies like HIVE Digital, Energy Vault, and OneMedNet, signaling a 'growth at all costs' or 'survival financing' strategy. The overall picture is one of a market where access to cheap capital is highly uneven, creating both acute risks and selective opportunities in distressed assets and well-capitalized survivors.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 30, 2026

This digest of 50 SEC filings reveals a pronounced theme of corporate distress and strategic restructuring across US public companies. A significant cluster of firms are actively managing liquidity and leverage through debt refinancing, asset sales, and equity offerings, often under duress. Key period-over-period trends include tightening financial covenants (e.g., HighPeak Energy's leverage ratio step-down) and a shift towards dilutive financing (e.g., Quantum Computing's authorized share increase, Eos Energy's rights offering). The most critical developments are multiple Nasdaq delisting warnings (Gulf Resources, SolarMax Technology) and a high volume of distressed asset sales (Sadot Group, Advanced Biomed) for nominal cash, signaling severe financial strain. A portfolio-level pattern is the reliance on single-lender credit facilities and complex, contingent financing structures, which introduce significant execution risk.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 29, 2026

This digest reveals a bifurcated corporate landscape on June 29, 2026, where aggressive M&A and financing activity (e.g., Martin Marietta's $13.5B acquisition, Rocket Lab/Iridium $8B merger) coexists with acute distress signals from micro-cap companies resorting to dilutive offerings and asset sales. The most critical theme is the 'cash-for-survival' pattern: multiple distressed entities (Volato, Datavault AI, U.S. GoldMining) are executing deeply dilutive financings or selling digital assets at a loss to stave off insolvency, while healthier firms are using cheap debt to consolidate. A notable period-over-period trend is the compression of margins in capital-intensive sectors (Honeywell Aerospace Q4 net income down 25% YoY) contrasted with high-margin recurring revenue models (Iridium's 57% OEBITDA margin). Insider activity is sparse but telling, with director resignations at Volato signaling governance risk. The forward-looking catalyst calendar is dense with Q3 2026 merger closes (TOMI/Carbonium, SandRidge, Martin Marietta) and a major mid-2027 close for the Rocket Lab/Iridium deal, creating a 12-month arbitrage window. The overarching takeaway: the market is rewarding scale and recurring cash flow while punishing companies with weak balance sheets and no clear path to profitability.

45 high priority 45 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 26, 2026

The 42 filings from June 26, 2026, paint a stark picture of corporate distress across the US public markets, with a heavy concentration of liquidity crises, covenant breaches, dilutive financing, and active bankruptcy proceedings. A dominant theme is the aggressive use of high-cost, convertible debt and preferred stock to stave off collapse, as seen at VEEA, Mobix Labs, and CERO Therapeutics, which are trading near-term liquidity for massive future dilution. Multiple companies, including Hallador Energy and RMX Industries, have secured covenant relief or maturity extensions from lenders, signaling acute financial pressure. The distress is sector-agnostic, hitting biotech (Matinas BioPharma, HCW Biologics), energy (Hallador), and technology (Upexi, SmartKem) alike. However, a notable counter-trend exists where fundamentally sound companies are executing strategic refinancings (Oceaneering, California Resources) or transformative M&A (H.B. Fuller, Bristow Group), indicating a bifurcated market where capital is available for strong credits but prohibitively expensive for the weak. The period-over-period data reveals a clear pattern of deteriorating equity bases, repeated covenant violations, and a reliance on insider-related financing as a last resort.

42 high priority 42 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 26, 2026

This digest of 42 SEC filings reveals a surge in corporate distress signals, particularly among small-cap life sciences and technology companies. The most critical developments include a Nasdaq delisting notice for Upexi, a second NYSE non-compliance notice for Matinas BioPharma, and a Chapter 11 overbid agreement for Charles & Colvard, indicating severe liquidity crises. A dominant theme is covenant-relief amendments, with Hallador Energy and RMX Industries securing breathing room from lenders, signaling financial strain. Conversely, a wave of opportunistic capital raising is underway, with ADP securing a $5.7B credit facility and Venture Global closing a $1.5B vessel financing, highlighting a bifurcated market where strong companies access cheap capital while distressed firms rely on dilutive or high-cost financing. Insider activity is limited, but the conversion of $4.1M in CEO debt to equity at Veea and the dilutive terms of Cero Therapeutics' note suggest management is using insider structures to manage cash burn. Forward-looking data points to a catalyst-rich period, with key data readouts from Vaxart and a merger deadline for Graf Global approaching in the coming weeks.

42 high priority 42 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 25, 2026

The June 25, 2026, filing batch reveals a bifurcated corporate landscape: while several companies are successfully accessing capital markets (Robinhood's $2.2B zero-coupon note, SharonAI's $1.6B raise) and executing strategic M&A (onsemi's $7B acquisition of Synaptics, PetVivo's acquisition of PiezoBioMembrane), a significant cohort is exhibiting acute distress signals. Multiple companies are teetering on the brink of bankruptcy or delisting, evidenced by Americas CarMart's waiver of anticipated defaults with a September 2026 deadline, Heron Therapeutics' Nasdaq bid price deficiency, and the high-risk 12% coupon on New Fortress Energy's Brazilian notes. The period-over-period data, where available, shows a stark contrast: Blue Owl Real Estate's 15% YoY revenue growth is overshadowed by an 87.5% decline in net realized gains, while Aytu BioPharma's Metadate CD product generated only $49,000 in quarterly revenue before its license was terminated. A critical theme is the prevalence of related-party and insider transactions (DSS/Alset, TerrAscend) that raise governance concerns, particularly as companies seek emergency financing. The overall sentiment is mixed, with a clear divergence between well-capitalized firms pursuing growth and cash-strapped entities fighting for survival.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 24, 2026

The 50 filings reveal a bifurcated corporate landscape on June 24, 2026, with acute distress signals concentrated in micro-cap and pre-revenue biotech/tech companies, while larger, established firms engage in routine capital management. The most critical developments include the imminent delisting of Aditxt (ADTX) and the high-risk reverse split at SRx Health Solutions (SRXH), both representing terminal distress. A significant theme is the aggressive use of reverse stock splits and dilutive financing by cash-strapped companies to maintain exchange listings, a pattern that has historically failed. Conversely, several companies are executing strategic pivots: Comstock Inc. sold legacy mining assets for $45M+ to focus on renewable metals, and Hyperscale Data secured a $1.2B+ AI compute contract, signaling a shift from crypto to AI infrastructure. The data also shows a wave of SPAC activity (Churchill Capital XI, Gores Holdings XI, Wilco 63) targeting AI and robotics, indicating strong market appetite for exposure to these themes. Period-over-period data, where available, shows revenue growth at Worksport (+47.9% YoY) and margin improvement, but this is overshadowed by the company's cash flow negativity. The overarching theme is a 'survival of the fittest' dynamic where companies with clear strategic direction and access to capital are thriving, while those with weak fundamentals and repeated compliance failures are facing extinction.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 23, 2026

The June 23, 2026, digest reveals heightened corporate distress across several US public companies, with two bankruptcy filings (Sangamo Therapeutics, Office Properties Income Trust) and multiple pre-bankruptcy distress signals including dilutive financings, delistings, and going concern warnings. A significant cluster of severe dilution events—notably AMC Entertainment raising $200M at a 19% discount, SharpLink Gaming diluting shareholders by 10M shares, and CIMG Inc.'s potentially catastrophic 43.3 billion share issuance—indicate acute liquidity crises among small/mid-cap firms. The period-over-period trends show a troubling pattern of 'distressed liability management,' where companies are trading equity for debt reduction or operating capital at depressed valuations. The credit markets present a bifurcated picture: blue-chip companies (IBM, PG&E, Fiserv) are easily refinancing at improved terms, while distressed issuers (Jack in the Box, Beazer Homes) face punitive rates (7.6% vs 4.5% prior). The most critical development is Sangamo's Chapter 11 filing, which serves as a bellwether for the biotech sector's ongoing cash crunch.

40 high priority 40 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — June 23, 2026

The June 23, 2026 bankruptcy/insolvency landscape is dominated by two distinctly structured restructurings: a completed Chapter 11 emergence (Office Properties Income Trust) and a new Chapter 11 filing with asset sales (Sangamo Therapeutics). OPIRQ's emergence involves complex tax gearing—massive cancellation of debt (COD) income offsetting NOLs and creating a NUBIL—which could pressure REIT qualification and future distributable income. Sangamo's filing triggers a stalking horse sale of core assets to Eli Lilly and Astellas for $75M+ in upfront/milestone payments, coupled with a $30M DIP facility, implying an imminent liquidation/run-off. Both filings reveal a sector theme of resource-constrained companies monetizing tax attributes (OPIRQ) or intellectual property (Sangamo) to satisfy creditors, with material insider trading signals notably absent, suggesting management teams are already disengaged or locked up post-restructuring. The combined period-over-period data is sparse due to the event-driven nature, but the forward-looking guidance hints at constrained operations for OPIRQ and a wind-down for Sangamo.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 22, 2026

Today's filings reveal a significant uptick in distress signals across micro-cap companies, with going concern risks, repeated defaults, and emergency equity offerings dominating the landscape. We see four companies in active liquidity crises (Algorhythm Holdings, Sable Offshore, Exyn Technologies) or warning of going concern uncertainty (CervoMed), while several others are forced to issue highly dilutive convertible notes or sell stock at deep discounts. A sharp bifurcation is evident: large-cap M&A (CRH/Arcosa, AbbVie/Apogee, Booz Allen) provides a bright spot, but for smaller firms, cash preservation through debt renegotiation, asset subleasing, and insider-funded advances is the prevailing theme. The average sentiment across all filings is neutral-to-mixed, with no sector-wide positive trends emerging in period-over-period comparisons as most filings lacked quantitative revenue or margin data. Key actionable insights include betting on the acquirers (CRH, AbbVie) and avoiding the most distressed micro-caps.

41 high priority 41 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 18, 2026

This digest covers 50 filings from June 18, 2026, revealing a pronounced bifurcation in corporate health. A clear theme is the aggressive use of capital markets by distressed companies to stave off insolvency, with 6 at-the-market (ATM) offerings and 3 private placements totaling over $500 million in potential dilution. Conversely, several firms are successfully refinancing debt on favorable terms, extending maturities by 2-4 years and improving balance sheet flexibility. The most critical distress signals are concentrated in micro-cap and pre-revenue biotech/tech companies, with 2 Nasdaq delisting notices (Dyadic International, Algorhythm Holdings) and one terminated SPAC merger (Papaya Growth Opportunity Corp. I). A notable sector theme is the high cost of distress financing, with companies like Nuvve Holding and CoreWeave agreeing to interest rates of 39% and 9.625% respectively, highlighting a two-tiered credit market. Insider trading data was sparse across these filings, but the prevalence of dilutive financing structures (convertible notes, preferred stock exchanges) signals significant shareholder value destruction for existing holders in distressed names.

50 high priority 50 total filings